Reuters Market Eye - * Neuland Laboratories
* Brokers say the pharma ingredient player is a strong re-rating candidate.
* Emkay says can generate very strong returns in two years.
* Neuland's earnings can grow at a compounded rate of 25 percent, adds Emkay.
* Trades at 8.7 times of 12-month forward earnings versus peer average of 41.78 times.
(Reporting by Abhishek Vishnoi)